Market closed

Immunic/$IMUX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Immunic

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Ticker

$IMUX
Trading on

Industry

Biotechnology

Employees

85
Website

Immunic Metrics

BasicAdvanced
$110M
Market cap
-
P/E ratio
-$1.12
EPS
1.88
Beta
-
Dividend rate
$110M
1.88
$1.84
$0.97
918K
2.709
2.564
0.451
2.181
-90.90%
-216.24%
2.67
2.67
-1.378
-62.58%
-33.83%

What the Analysts think about Immunic

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Immunic stock.

Immunic Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immunic Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMUX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immunic stock?

Immunic (IMUX) has a market cap of $110M as of December 06, 2024.

What is the P/E ratio for Immunic stock?

The price to earnings (P/E) ratio for Immunic (IMUX) stock is 0 as of December 06, 2024.

Does Immunic stock pay dividends?

No, Immunic (IMUX) stock does not pay dividends to its shareholders as of December 06, 2024.

When is the next Immunic dividend payment date?

Immunic (IMUX) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunic?

Immunic (IMUX) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.